GlaxoSmithKline Pharmaceuticals Limited has issued a clarification to stock exchanges regarding a significant increase in trading volumes of its securities, attributing the surge to market-driven factors while confirming full regulatory compliance.

Exchange Communication and Regulatory Compliance

In response to queries from BSE Limited and the National Stock Exchange of India Limited dated December 31, 2025, the pharmaceutical company provided detailed clarification about the recent volume spike. The company emphasized that it has made all necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time.

Volume Increase Attribution

The company categorically stated that the significant increase in trading volume is purely market driven. GlaxoSmithKline Pharmaceuticals clarified that it has not withheld any material information or events that could have a bearing on the company's operations or performance, including all price-sensitive information.

The pharmaceutical major assured that it maintains transparency in its communications with stakeholders and regulatory bodies. The company's response indicates that no specific corporate developments or undisclosed events contributed to the increased trading activity.

Ongoing Compliance Commitment

GlaxoSmithKline Pharmaceuticals reiterated its commitment to maintaining compliance with listing regulation requirements. The company assured exchanges that it will continue to keep them informed of all price-sensitive information as and when such information arises.

The clarification was signed by Ajay Nadkarni, who serves as Vice President - Administration, Real Estate & Company Secretary, demonstrating the company's formal approach to regulatory communications and transparency obligations.

GlaxoSmithKline Pharmaceuticals Limited has informed stock exchanges about receiving a significant GST demand order from West Bengal State GST authorities. The pharmaceutical company disclosed this development under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

GST Demand Order Details

The demand order, amounting to ₹89.59 lakh, was issued by the Joint Commissioner, State Tax, Large Taxpayer Unit, West Bengal State GST. The order pertains to credit mismatch issues between the company's GST returns and the details reported by its suppliers.

Nature of GST Issues

The GST authorities have raised the demand in relation to GST credit-related issues. The primary concern involves a major credit mismatch between the company's GST returns and the details reported by its suppliers. This type of discrepancy typically arises when there are differences in the input tax credit claimed by the company and the corresponding output tax reported by vendors.

Company's Response and Impact Assessment

GlaxoSmithKline Pharmaceuticals has stated that it is currently evaluating the demand order. The company plans to take appropriate action in response to the order. As of now, the company has not provided specific details on the potential impact on its financial operations.

Regulatory Compliance

The company has fulfilled its disclosure obligations by informing the stock exchanges about this development. The disclosure was made in accordance with the regulatory requirements for material events that could potentially affect stakeholder interests.

GlaxoSmithKline Pharmaceuticals' proactive disclosure demonstrates its commitment to transparency and regulatory compliance, even as it works to address the GST-related concerns raised by the West Bengal authorities.